– WATCH
Learn more about Bexion Pharmaceuticals through our highlights video
– WATCH
Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson
In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.
– WATCH
Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.
Bexion in Innovation Express
Innovation Express is a multi-media healthcare news hub designed to share all Innovation Healthcare Institute (IHCI) events and programs and announce the most innovative items in healthcare. Bexion Pharmaceuticals, Inc. was recently featured in Innovations Express. Please click on the link below to read the article and learn more about our organization.
– Our Platform
An innovative, targeted approach to treating cancer
For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.
By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. to Present at the 2022 Association for Cancer Immunotherapy (CIMT) Annual Meeting
FOR IMMEDIATE RELEASE [Covington, KY---May 10, 2022 ] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for the CIMT annual meeting to be held in Mainz, Germany, May 10-12, 2022 has been chosen for poster presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the ... Read More
Bexion Pharmaceuticals Announces Leadership Additions
The new leadership roles support the company’s momentum in becoming the leader in developing and commercializing therapeutics based on exploiting the lysosome to treat challenging solid tumors as well as chemotherapy-induced peripheral neuropathy (CIPN). FOR IMMEDIATE RELEASE [Covington, KY---February 2, 2022] Bexion Pharmaceuticals, a clinical stage biopharmaceutical company, today announced key leadership changes, including the ... Read More